Literature DB >> 28989002

CHI3L1 and CHI3L2 overexpression in motor cortex and spinal cord of sALS patients.

C Sanfilippo1, A Longo1, F Lazzara1, D Cambria1, G Distefano1, M Palumbo1, A Cantarella1, L Malaguarnera1, M Di Rosa2.   

Abstract

BACKGROUND: Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive neurodegenerative disease characterized by the degeneration and death of upper (UMN) and lower (LMN) motor neurons. In the last decade, it has been shown that Chitinases are an important prognostic indicator of neuro-inflammatory damage induced by microglia and astrocytes.
MATERIALS AND METHODS: We analyzed microarray datasets obtained from the Array Express in order to verify the expression levels of CHI3L1 and CHI3L2 in motor cortex biopsies of sALS patients with different survival times. We also divided the sALS patients into smokers and non-smokers. In order to extend our analysis, we explored two additional microarray datasets, GSE833 and GSE26927, of post-mortem spinal cord biopsies from sALS patients.
RESULTS: The analysis showed that CHI3L1 and CHI3L2 expression levels were significantly upregulated in the motor cortex of sALS patients, compared to the healthy controls. Moreover, their expression levels were negatively correlated with survival time. Interesting results were obtained when we compared the expression levels of Chitinases among smokers. We showed that CHI3L1 and CHI3L2 were significantly upregulated in sALS smokers compared to non-smokers. Furthermore, we found that four genes belonging to the Chitinases network (SERPINA3, C1s, RRAD, HLA-DQA1) were significantly upregulated in the motor cortex of sALS patients and positively correlated with Chitinases expression levels. Similar results were obtained during the exploration of the two-microarray dataset.
CONCLUSIONS: This study suggests that CHI3L1 and CHI3L2 are associated with the progression of neurodegeneration in motor cortex and spinal cord of sALS patients.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C1s; CHI3L1; CHI3L2; Motor cortex; SERPINA3; sALS

Mesh:

Substances:

Year:  2017        PMID: 28989002     DOI: 10.1016/j.mcn.2017.10.001

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  24 in total

1.  Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.

Authors:  Ione O C Woollacott; Jennifer M Nicholas; Carolin Heller; Martha S Foiani; Katrina M Moore; Lucy L Russell; Ross W Paterson; Ashvini Keshavan; Jonathan M Schott; Jason D Warren; Amanda Heslegrave; Henrik Zetterberg; Jonathan D Rohrer
Journal:  Dement Geriatr Cogn Disord       Date:  2020-04-28       Impact factor: 2.959

2.  Neurorescuing effect of Cinacalcet against hypercalcemia-induced nerve injury in chronic kidney disease via TRAF2/cIAP1/KLF2/SERPINA3 signal axis.

Authors:  Yaochen Cao; Yingquan Xiong; Hongming Sun; Ziqiang Wang
Journal:  Cell Biol Toxicol       Date:  2022-05-30       Impact factor: 6.691

3.  A sex-stratified analysis of neuroimmune gene expression signatures in Alzheimer's disease brains.

Authors:  Cristina Sanfilippo; Paola Castrogiovanni; Manlio Vinciguerra; Rosa Imbesi; Martina Ulivieri; Francesco Fazio; Kaj Blennow; Henrik Zetterberg; Michelino Di Rosa
Journal:  Geroscience       Date:  2022-09-22       Impact factor: 7.581

4.  Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance.

Authors:  Arianna Colini Baldeschi; Marco Zattoni; Silvia Vanni; Lea Nikolic; Chiara Ferracin; Giuseppina La Sala; Maria Summa; Rosalia Bertorelli; Sine Mandrup Bertozzi; Gabriele Giachin; Paolo Carloni; Maria Laura Bolognesi; Marco De Vivo; Giuseppe Legname
Journal:  J Med Chem       Date:  2022-06-30       Impact factor: 8.039

5.  Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer's disease.

Authors:  Kevin Connolly; Mikael Lehoux; Ryan O'Rourke; Benedetta Assetta; Guzide Ayse Erdemir; Jack A Elias; Chun Geun Lee; Yu-Wen Alvin Huang
Journal:  Alzheimers Dement       Date:  2022-03-02       Impact factor: 16.655

6.  Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis.

Authors:  Shotaro Haji; Wataru Sako; Nagahisa Murakami; Yusuke Osaki; Yuishin Izumi
Journal:  J Neural Transm (Vienna)       Date:  2022-02-18       Impact factor: 3.850

7.  GFAP Mutations in Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease.

Authors:  Li Li; E Tian; Xianwei Chen; Jianfei Chao; Jeremy Klein; Qiuhao Qu; Guihua Sun; Guoqiang Sun; Yanzhou Huang; Charles D Warden; Peng Ye; Lizhao Feng; Xinqiang Li; Qi Cui; Abdullah Sultan; Panagiotis Douvaras; Valentina Fossati; Neville E Sanjana; Arthur D Riggs; Yanhong Shi
Journal:  Cell Stem Cell       Date:  2018-08-02       Impact factor: 24.633

8.  GNG13 Is a Potential Marker of the State of Health of Alzheimer's Disease Patients' Cerebellum.

Authors:  Cristina Sanfilippo; Giuseppe Musumeci; Maria Kazakova; Venera Mazzone; Paola Castrogiovanni; Rosa Imbesi; Michelino Di Rosa
Journal:  J Mol Neurosci       Date:  2020-10-15       Impact factor: 3.444

9.  Serpin Signatures in Prion and Alzheimer's Diseases.

Authors:  Marco Zattoni; Marika Mearelli; Silvia Vanni; Arianna Colini Baldeschi; Thanh Hoa Tran; Chiara Ferracin; Marcella Catania; Fabio Moda; Giuseppe Di Fede; Giorgio Giaccone; Fabrizio Tagliavini; Gianluigi Zanusso; James W Ironside; Isidre Ferrer; Giuseppe Legname
Journal:  Mol Neurobiol       Date:  2022-04-13       Impact factor: 5.682

10.  The expression levels of CHI3L1 and IL15Rα correlate with TGM2 in duodenum biopsies of patients with celiac disease.

Authors:  Paola Catrogiovanni; Giuseppe Musumeci; Salvatore Giunta; Rosa Imbesi; Michelino Di Rosa
Journal:  Inflamm Res       Date:  2020-06-04       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.